RADNOR, Pa., March 31, 2025 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that securities class action lawsuits have been filed against Geron Corporation ("Geron") (NASDAQ: GERN) on behalf of those who purchased or otherwise acquired Geron securities between February 28, 2024, and February 25, 2025, inclusive (the "Class Period"). The lead plaintiff deadline is May 12, 2025. The complaints allege that, throughout the Class Period, Defendants made false a ...

SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Geron Corporation (NASDAQ: GERN) securities between February 28, 2024 and February 25, 2025, inclusive (the "Class Period"), have until Monday, May 12, 2025 to seek appointment as lead plaintiff of the Geron class action lawsuit. Captioned Dabestani v. Geron Corporation, No. 25-cv-02507 (N.D. Cal.), the Geron class action lawsuit charges Geron and certain of Geron's top current and former ...

Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Geron Corporation (NASDAQ: GERN ) has only reported two full quarters of sales of Rytelo (imetelstat) ...

SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Geron Corporation (NASDAQ: GERN) securities between June 7, 2024 to February 25, 2025. Geron is a commercial-stage biopharmaceutical company with a focus on blood cancer. Geron's primary product is a telomerase inhibitor, imetelstat, which the Company sells under the brand name, Rytelo. Attorney Advertising. Past results do not guarantee ...

CONTACT US HERE: https://securitiesclasslaw.com/securities/geron-corporation-loss-submission-form/?id=139419&from=4 CLASS PERIOD: February 28, 2024 to February 25, 2025 ALLEGATIONS: According to the complaint, defendants provided investors with material information concerning defendants' expectations for the launch and growth potential of Rytelo (imetelstat). Defendants' statements included, among other things, confidence in Geron's ability to capitalize on the purportedly significant unmet need for the dru ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Geron Corporation securities between February 28, 2024, and February 25, 2025, of the May 12, 2025, lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - Investors who purchased Geron securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by May 12, 2025 [2] - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [5] Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [3] - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time, and has consistently ranked highly in securities class action settlements since 2013 [3] - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [3] Group 3: Case Allegations - The lawsuit alleges that Geron Corporation made false and misleading statements regarding the market potential and profitability of its drug RYTELO, which were not disclosed to investors [4] - Key issues include a lack of awareness among healthcare providers, monitoring requirements, seasonality, and competition that would impair Geron's ability to capitalize on the drug's market potential [4] - As a result of these misrepresentations, Geron's business and financial prospects were overstated, leading to investor damages when the true information became public [4]

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Geron To Contact Him Directly To Discuss Their OptionsIf you suffered losses exceeding $100,000 in Geron between February 28, 2024 to February 25, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, March 28, 2025 /PRNewswir ...

LOS ANGELES, March 28, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Geron Corporation ("Geron" or "the Company") (NASDAQ: GERN) for violations of the federal securities laws.Shareholders who purchased the Company's securities between June 7, 2024 and February 25, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before May 12, 2025.     CASE DETAILS:  According to the Complaint the company allegedly made misleading statements that gave inv ...

NEW YORK, March 28, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Geron Corporation ("Geron" or the "Company") (NASDAQ: GERN) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Geron investors who were adversely affected by alleged securities fraud between June 7, 2024 and February 25, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/geron-corporation-lawsuit-submission ...

Core Viewpoint - A class action lawsuit has been filed against Geron Corporation for allegedly misleading investors about the launch and growth potential of its drug Rytelo, a telomerase inhibitor for blood cancer treatment [1][2][3]. Allegations - The lawsuit claims that Geron did not disclose that the optimistic reports regarding Rytelo's launch success were not reflective of reality, as factors like seasonality, competition, and monitoring burdens significantly impacted patient starts [3]. - It is alleged that Rytelo lacked sufficient market awareness, hindering Geron's ability to meet the unmet need for the drug, especially among first-line patients and those outside academic settings [3]. Financial Impact - On February 26, 2025, Geron reported its fourth-quarter financial results for fiscal 2024, revealing that Rytelo's growth had stagnated, attributing this to seasonality, competition, lack of awareness, and monitoring requirements [4]. - Following this announcement, Geron's stock price plummeted from $2.37 per share on February 25, 2025, to $1.61 per share on February 26, 2025, marking a decline of approximately 32.07% in one day [4]. Class Action Participation - Shareholders may be eligible to participate in the class action against Geron Corporation, with a deadline to file as lead plaintiff by May 12, 2025 [5]. - Shareholders can choose to remain absent class members without participating in the case [5]. Company Background - Robbins LLP is noted as a leader in shareholder rights litigation, focusing on helping shareholders recover losses and improve corporate governance since 2002 [6].